JNJ-37654032

JNJ-37654032 is a selective androgen receptor modulator which was developed by Johnson & Johnson for the potential treatment of muscular atrophy but was never marketed.
The drug is a nonsteroidal androgen receptor modulator with mixed agonistic and antagonistic effects. In animals, it has shown full agonist-like effects in muscle, agonistic suppressive effects on follicle-stimulating hormone secretion, and antagonistic or partially agonistic effects in the prostate. It was the lead compound of a novel benzimidazole series of SARMs described as being reminiscent of but distinct from the arylpropionamides.
JNJ-37654032 did not advance past the preclinical research and was never tested in humans. It was first described in the scientific literature by 2008.